• LAST PRICE
    22.0000
  • TODAY'S CHANGE (%)
    Trending Up0.5200 (2.4209%)
  • Bid / Lots
    21.9800/ 2
  • Ask / Lots
    22.0300/ 1
  • Open / Previous Close
    21.5000 / 21.4800
  • Day Range
    Low 21.3600
    High 22.7700
  • 52 Week Range
    Low 17.3300
    High 87.1900
  • Volume
    238,048
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 21.48
TimeVolumeZNTL
09:32 ET353421.71
09:34 ET40021.63
09:36 ET60021.675
09:38 ET20921.645
09:39 ET220021.63
09:41 ET60021.61
09:43 ET30021.78
09:45 ET10021.835
09:48 ET115821.85
09:52 ET40022.02
09:54 ET10022.11
09:56 ET10022.01
09:57 ET10022.17
09:59 ET85222.155
10:01 ET20021.945
10:03 ET50021.99
10:06 ET150021.93
10:08 ET30022
10:10 ET150021.95
10:12 ET40021.97
10:14 ET50022.03
10:15 ET275722.055
10:19 ET193922.2
10:21 ET70022.16
10:24 ET95422.215
10:26 ET90022.32
10:28 ET386022.2
10:32 ET160022.24
10:33 ET30022.24
10:35 ET50022.305
10:37 ET215322.24
10:42 ET157122.25
10:44 ET50022.35
10:48 ET140022.395
10:50 ET170022.48
10:51 ET107522.46
10:53 ET50022.455
10:55 ET60022.45
10:57 ET120022.47
11:00 ET70022.55
11:02 ET182522.49
11:04 ET120822.42
11:06 ET92522.45
11:08 ET150022.465
11:09 ET130022.63
11:11 ET144622.63
11:13 ET50022.58
11:15 ET20022.56
11:18 ET194922.5
11:20 ET110022.575
11:22 ET40022.62
11:24 ET30022.6
11:26 ET55122.64
11:27 ET40022.665
11:29 ET120022.68
11:31 ET30022.67
12:09 ET80022.425
12:12 ET40022.475
12:14 ET40022.475
12:16 ET90022.4
12:18 ET80022.415
12:20 ET144222.4
12:21 ET40022.39
12:23 ET90022.4
12:25 ET113222.485
12:27 ET70022.52
12:30 ET330022.555
12:32 ET76322.665
12:34 ET30022.7
12:36 ET80022.67
12:38 ET30022.74
12:39 ET10022.74
12:41 ET20022.75
12:43 ET50022.74
12:45 ET90022.675
12:48 ET60022.67
12:50 ET60022.73
12:52 ET60022.68
12:54 ET30022.63
12:56 ET160022.635
12:57 ET90022.67
12:59 ET30022.64
01:01 ET60022.6
01:03 ET10022.55
01:06 ET20022.55
01:08 ET300022.55
01:10 ET148822.57
01:12 ET100022.6
01:14 ET20022.605
01:15 ET100022.56
01:17 ET100022.515
01:21 ET20022.59
01:24 ET50022.58
01:26 ET174022.535
01:28 ET90022.57
01:30 ET57922.63
01:32 ET40022.625
01:33 ET70022.59
01:35 ET30022.575
01:37 ET224322.4
01:39 ET60022.405
01:42 ET110022.425
01:44 ET94022.37
01:46 ET60022.355
01:48 ET110022.32
01:50 ET30022.31
01:51 ET90022.33
01:53 ET203022.38
01:55 ET170222.31
01:57 ET10022.315
02:00 ET150022.3
02:02 ET100022.32
02:06 ET140022.29
02:08 ET359822.33
02:09 ET200022.32
02:11 ET130022.325
02:13 ET250022.3
02:15 ET200022.32
02:18 ET661822.34
02:20 ET80022.3
02:22 ET90022.3
02:24 ET133422.36
02:26 ET70022.3
02:27 ET330022.22
02:29 ET186922.25
02:31 ET70022.23
02:33 ET175222.12
02:36 ET340722.14
02:38 ET305322.06
02:40 ET121822.04
02:42 ET160022.02
02:44 ET139822.035
02:45 ET98122
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesZNTL
Zentalis Pharmaceuticals Inc
1.2B
-5.7x
---
United StatesCINC
CinCor Pharma Inc
1.2B
0.0x
---
United StatesAKRO
Akero Therapeutics Inc
1.2B
-10.9x
---
United StatesRYTM
Rhythm Pharmaceuticals Inc
1.1B
-7.0x
---
United StatesGOSS
Gossamer Bio Inc
1.1B
-4.0x
---
United StatesSANA
Sana Biotechnology Inc
1.1B
-3.7x
---
As of 2022-09-30

Company Information

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company's products include ZN-c5 and ZN-c3. ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and advanced or metastatic breast cancer. The Company engaged in initiating the Phase II monotherapy and combination portions of this Phase I/II trial. ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, is being evaluated in a Phase I/II clinical trial for the treatment of advanced solid tumors as a monotherapy and in a Phase Ib clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. It uses its Integrated Discovery Engine to identify targets and develop small molecule chemical entities with properties.

Contact Information

Headquarters
1359 Broadway, Suite 1710, Suite 2201NEW YORK, NY, United States 10018
Phone
212-433-3791
Fax
302-636-5454

Executives

Independent Chairman of the Board
David Johnson
President, Executive Director
Cam Gallagher
Chief Executive Officer, Director
Kimberly Blackwell
Chief Financial Officer, Treasurer
Melissa Epperly
Interim Principal Executive Officer, Chief Operating Officer
Kevin Bunker

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.2B
Revenue (TTM)
$0.00
Shares Outstanding
57.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.85
Book Value
$8.00
P/E Ratio
-5.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.